protein

Recombinant Human Vascular Endothelial Growth Factor receptor-1 D1-7

MBS142787

0.01 mg

205 USD

Recombinant Protein

Recombinant Human Vascular Endothelial Growth Factor receptor-1 D1-7

Vascular Endothelial Growth Factor receptor-1 D1-7

FLT1 D7 Human; Vascular Endothelial Growth Factor Receptor-1 D1-7 Human Recombinant; FLT-1; FLT1; Tyrosine-protein kinase receptor FLT; Flt-1; Tyrosine-protein kinase FRT; Fms-like tyrosine kinase 1; VEGFR-1; FLT1 D7

vascular endothelial growth factor receptor 1 isoform 2; Vascular endothelial growth factor receptor 1; vascular endothelial growth factor receptor 1; fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); tyrosine-protein kinase FRT; tyrosine-protein kinase receptor FLT; fms-related tyrosine kinase 1; Fms-like tyrosine kinase 1; FLT-1; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; FLT; Vascular permeability factor receptor

FLT1

FLT1; FLT1; FLT; FLT-1; VEGFR1; VEGFR-1; FLT; FRT; VEGFR1; VEGFR-1; FLT-1; FLT

VGFR1_HUMAN

Insect Cells

687

SGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSL
PEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHT
GFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSE
IPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPD
GKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTN
YLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPL
NTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLT
IDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITV
KHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLP
ATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNV
FKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILT
CTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFIL
DADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISG
IYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEG
EDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKM
AITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEIL
QKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGV
PEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDE
GVYHCKATNQKGSVESSAYLTVQGTRSDKTHTCPPCPAP
ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP
EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK.

Greater than 95.0% as determined by SDS-PAGE.

FLT1 D1-7 was lyophilized from a concentrated (1 mg/ml) sterile solution containing PBS Buffer, pH 7.4. Sterile Filtered White lyophilized (freeze-dried) powder.

Lyophilized FLT-1 although stable at room temperature for 3 weeks, should be stored desiccated below -18C. Upon reconstitution FLT1 should be stored at 4C between 2-7 days and for future use below -18C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Solubility: It is recommended to reconstitute the lyophilized FLT1 Fc/Chimera in PBS not less than 50 ug/ml, which can then be further diluted to other aqueous solutions. Biological Activity: The activity of FLT1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.

PROTEIN KINASES; Enzymes; VEGF Receptors

Description: Soluble FLT1 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is disulfide-linked homodimeric, glycosylated, polypeptide containing 751 amino acids and having a molecular mass of 130 kDa. The soluble receptor protein contains only the first 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. The FLT1 fc/Chimera is purified by proprietary chromatographic techniques. Introduction: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin.

229892220

NP_001153392.1

NM_001159920.1

P17948

41,175 Da

Angiogenesis Pathway 198772!!Cytokine-cytokine Receptor Interaction Pathway 83051!!Cytokine-cytokine Receptor Interaction Pathway 460!!Endocytosis Pathway 102279!!Endocytosis Pathway 102181!!Focal Adhesion Pathway 198795!!Focal Adhesion Pathway 83067!!Focal Adhesion Pathway 478!!Glypican 1 Network Pathway 138010!!HIF-1 Signaling Pathway 695200

This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened, soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.[provided by RefSeq, May 2009]

0.01 mg

205 USD